Central nervous system involvement in adult acute lymphocytic leukemia

Hematology/Oncology Clinics of North America

Volumn 15, Issue 1, 2001, Pages 145-162

  Cortes, J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; BETA 2 MICROGLOBULIN; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; HYDROCORTISONE; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; STEROID;

ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; DRUG INDUCED DISEASE; HUMAN; NEUROTOXICITY; PRIORITY JOURNAL; PROGNOSIS; PROPHYLAXIS; REVIEW; RISK FACTOR; SKULL IRRADIATION; TREATMENT OUTCOME;

EID: 0035096476     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(05)70203-3     Document Type: Article

References (92)

1. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia
2. Differences in cerebrospinal fluid penetration of corticosteroids: Possible relationship to the prevention of meningeal leukemia
3. Central nervous system pharmacology of antileukemic drugs
4. Remission induction of meningeal leukemia with high-dose intravenous methotrexate
5. Current pharmacological treatment approaches to central nervous system leukaemia
6. Intrathecal administration of topotecan in nonhuman primates
7. Central nervous system leukemia
8. Neurologic sequelae of methotrexate and ionizing radiation: A new classification
9. Prophylaxis and treatment of leukemia in the central nervous system and other sanctuaries
10. Adult acute lymphocytic leukemia: The Eastern Cooperative Oncology Group experience
11. Treatment of leptomeningeal metastasis with intraventricular administration of depot cytarabine (DTC 101): A phase I study
12. Leptomeningeal metastasis: A comparison of gadolinium-enhanced MR and contrast-enhanced CT of the brain
13. The role of radiation therapy in the treatment of acute lymphoblastic leukemia with lymphomatous presentation: A report from the Children's Cancer Group
14. Detection of DNA abnormalities by flow cytometry in cells from cerebrospinal fluid
15. Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Munster-based intensive chemotherapy
16. The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia
17. Neurobehavioral sequelae of cranial irradiation in adults: A review of radiation-induced encephalopathy
18. Levels of L-asparagine in CSF after intramuscular administration of asparaginase from Erwinia in children with acute lymphoblastic leukemia
19. Results of Medical Research Council trial UKALL IX in acute lymphoblastic leukaemia in adults: Report from the Medical Research Council Working Party on Adult Leukaemia
20. Comparative brain tissue distribution of camptothecin and topotecan in the rat
21. The increasing incidence of central nervous system leukemia in children
22. Adult acute lymphoblastic leukemia: A multicentric randomized trial testing bone marrow transplantation as postremission therapy
23. The importance of an isolated central nervous system relapse in children with acute lymphoblastic leukemia
24. Low numbers of CSF blasts at diagnosis do not predict for the development of CNS leukemia in children with intermediate-risk acute lymphoblastic leukemia: A Children's Cancer Group report
25. Malignant cells in cerebrospinal fluid (CSF): The meaning of a positive CSF cytology
26. Outcome of CNS disease at diagnosis in disseminated small noncleaved-cell lymphoma and B-cell leukemia: A Children's Cancer Group study
27. Meningeal leukemia
28. Improved outcome in adult B-cell acute lymphoblastic leukemia
29. Intensified therapy in acute lymphoblastic and acute undifferentiated leukemia in adults
30. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults
31. Treatment of acute lymphoblastic leukemia in adults with intensive induction, consolidation, and maintenance chemotherapy
32. Intrathecal chemotherapy for treatment of overt meningeal leukemia: Comparison between intraventricular and traditional intralumbar route
33. Comparative cytotoxicity of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia
34. Cardiac dysfunction following spinal irradiation during childhood
35. Molecular evidence for central nervous system involvement in children with newly diagnosed acute lymphoblastic leukemia
36. Lower incidence of meningeal leukemia when prednisone is replaced by dexamethasone in the treatment of acute lymphocytic leukemia
37. Intensive treatment of children with acute lymphoblastic leukemia according to ALL-BFM-86 without cranial radiotherapy: Results of Dutch Childhood Leukemia Study Group Protocol ALL-7 (1988-1991)
38. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia
39. Identification of risk groups for development of central nervous system leukemia in adults with acute lymphocytic leukemia
40. Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard- and high-risk acute lymphocytic leukemia
41. Prognostic significance of elevated serum beta 2-microglobulin levels in adult acute lymphocytic leukemia
42. Leptomeningeal metastases: Comparison of clinical features and laboratory data of solid tumors, lymphomas and leukemias
43. A strategy for evaluation of new treatments in untreated patients: Application to a clinical trial of AMSA for acute leukemia
44. Elevation of cerebrospinal fluid soluble CD27 levels in patients with meningeal localization of lymphoid malignancies
45. A pilot study of intermediate-dose methotrexate and cytosine arabinoside, "spread-out" or "up-front," in continuation therapy for childhood non-T, non-B acute lymphoblastic leukemia
46. Comparison of maintenance treatment regimens for first central nervous system relapse in children with acute lymphocytic leukemia
47. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leukemia Group B study 8811
48. The role of prophylactic brain irradiation in limited stage small cell lung cancer: Clinical, neuropsychologic, and CT sequelae
49. Treatment of adult acute lymphoblastic leukemia with intensive cyclical chemotherapy: A follow-up report
50. Improved results of an intensified therapy in adult acute lymphocytic leukemia
51. Secondary neoplasms subsequent to Berlin-Frankfurt-Munster therapy of acute lymphoblastic leukemia in childhood: Significantly lower risk without cranial radiotherapy
52. Low leukocyte counts with blast cells in cerebrospinal fluid of children with newly diagnosed acute lymphoblastic leukemia
53. Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: An association with intermediate-dose intravenous methotrexate and intrathecal triple therapy - A Pediatric Oncology Group study
54. Intermediate-dose intravenous methotrexate with intravenous mercaptopurine is superior to repetitive low-dose oral methotrexate with intravenous mercaptopurine for children with lower-risk B-lineage acute lymphoblastic leukemia: A Pediatric Oncology Group phase III trial
55. The GIMEMA ALL 0183 trial: Analysis of 10-year follow-up
56. Report and recommendations of the Rome workshop concerning poor-prognosis acute lymphoblastic leukemia in children: Biologic bases for staging, stratification, and treatment
57. Diagnosis of leukemia or lymphoma in the central nervous system by beta 2-microglobulin determination
58. Systemic high-dose ara-C for the treatment of meningeal leukemia in adult acute lymphoblastic leukemia and non-Hodgkin's lymphoma
59. A prospective comparison of neuropsychologic performance of children surviving leukemia who received 18-Gy, 24-Gy, or no cranial irradiation
60. Molecular evidence for minimal residual bone marrow disease in children with 'isolated' extra-medullary relapse of T-cell acute lymphoblastic leukemia
61. Combination chemotherapy of adult acute lymphoblastic leukemia with randomized central nervous system prophylaxis
62. Factors that influence the appearance of central nervous system leukemia
63. Acute lymphoblastic leukemia in children
64. Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia
65. Extended triple intrathecal chemotherapy trial for prevention of CNS relapse in good-risk and poor-risk patients with B-progenitor acute lymphoblastic leukemia: A Pediatric Oncology Group study
66. Adult acute lymphoblastic leukemia: Results of the Iowa HOP-L protocol
67. Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: A BFM group report
68. Etoposide achieves potentially cytotoxic concentrations in CSF of children with acute lymphoblastic leukemia
69. High incidence of secondary brain tumours after radiotherapy and antimetabolites
70. An intensive re-treatment protocol for children with an isolated CNS relapse of acute lymphoblastic leukemia
71. L-Asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans
72. Improved survival of children with isolated CNS relapse of acute lymphoblastic leukemia: A Pediatric Oncology Group study
73. Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy
74. Effects of different forms of central nervous system prophylaxis on neuropsychologic function in childhood leukemia
75. Treatment of acute lymphoblastic leukemia in adults: Results of the L-10 and L-10M protocols
76. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: Results of trial ALL-BFM 90
77. Effect of spinal irradiation on growth
78. The accumulation of topotecan in 9L glioma and in brain parenchyma with and without dexamethasone administration
79. Natural history of central nervous system acute leukemia in adults
80. Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia
81. The risks of central nervous system relapse and leukoencephalopathy in patients receiving marrow transplants for acute leukemia
82. Eighty-one percent event-free survival in advanced Burkitt's lymphoma/leukemia: No differences in outcome between pediatric and adult patients treated with the same intensive pediatric protocol
83. Blasts in CSF with a normal cell count do not justify alteration of therapy for acute lymphoblastic leukemia in remission: A Children's Cancer Group study
84. Prevention of CNS disease in intermediate-risk acute lymphoblastic leukemia: Comparison of cranial radiation and intrathecal methotrexate and the importance of systemic therapy: A Children's Cancer Group report
85. Minimal neuropsychological sequelae following prophylactic treatment of the central nervous system in adult leukaemia and lymphoma
86. Impact of preexisting CNS involvement on the outcome of bone marrow transplantation in adult hematologic malignancies
87. Cranial irradiation is the major cause of learning problems in children treated for leukemia and lymphoma: A comparative study
88. Toxicity of CNS prophylaxis for childhood leukemia
89. Secondary brain tumors in children treated for acute lymphoblastic leukemia at St Jude Children's Research Hospital
90. Long-term follow-up of treatment and potential cure of adult acute lymphocytic leukemia with MOAD: A non-anthracycline containing regimen
91. Leptomeningeal metastases: MR evaluation
92. Phase I and clinical pharmacological study of mercaptopurine administered as a prolonged intravenous infusion